Axonics (AXNX) Stock Price, News & Analysis

Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Key Stats

• Today's Range: $70.37 to $71.05
• 50-Day Range: $69.66 to $70.98
• 52-Week Range: $55.09 to $71.05
• Volume: 4.23 million shs
• Average Volume: 713,457 shs
• Market Capitalization: $3.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $71.00
• Consensus Rating: Hold

Axonics Stock Analysis - MarketRank™

Axonics scored higher than 23% of companies evaluated by MarketBeat, and ranked 871st out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Axonics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 8 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Axonics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 300.00%

Earnings Growth

Earnings for Axonics are expected to grow by 300.00% in the coming year, from $0.22 to $0.88 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Axonics is -591.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Axonics is -591.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Axonics has a P/B Ratio of 5.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AXNX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Axonics does not currently pay a dividend.

Dividend Growth

Axonics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -1.38

Short Interest

There is no current short interest data available for AXNX.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Axonics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Axonics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $205,523.00 in company stock.

Percentage Held by Insiders

Only 1.85% of the stock of Axonics is held by insiders.

Percentage Held by Institutions

99.48% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AXNX Stock Analysis - Frequently Asked Questions

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) issued its quarterly earnings data on Thursday, August, 1st. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.03. The company's revenue was up 23.3% on a year-over-year basis.

When did Axonics IPO?

Axonics (AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Who are Axonics' major shareholders?

Top institutional investors of Axonics include Alpine Associates Management Inc. (4.26%), Westchester Capital Management LLC (2.84%), Geode Capital Management LLC (2.35%) and State Street Corp (2.32%). Insiders that own company stock include Raymond W Cohen, John Woock, Rinda Sama, Kari Leigh Keese, Alfred J Ford Jr, Karen Noblett, Danny L Dearen, Jane E Kiernan and Esteban Lopez.
View institutional ownership trends.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Axonics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), NVIDIA (NVDA), TotalEnergies (TTE) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 8/01/2024
• Today: 12/17/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:AXNX
• CUSIP: N/A
• CIK: 1603756
• Web: www.axonics.com
• Phone: (949) 396-6322
• Fax: 949-396-6321
• Employees: 610
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $71.00
• High Stock Price Target: $71.00
• Low Stock Price Target: $71.00
• Potential Upside/Downside: +0.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 322.64
• P/E Growth: N/A
• Net Income: $-6,090,000.00
• Net Margins: -1.31%
• Pretax Margin: -0.70%
• Return on Equity: 0.36%
• Return on Assets: 0.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.16
• Quick Ratio: 6.40

Sales & Book Value

• Annual Sales: $366.38 million
• Price / Sales: 9.90
• Cash Flow: $0.13 per share
• Price / Cash Flow: 561.96
• Book Value: $12.59 per share
• Price / Book: 5.64

Miscellaneous

• Outstanding Shares: 51,110,000
• Free Float: 50,163,000
• Market Cap: $3.63 billion
• Optionable: Optionable
• Beta: 0.82